Break throughthe PAM barrier.
Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer. Our lead candidate PIKTOR is an all-oral combination that is designed to achieve deeper pathway suppression with greater tolerability by targeting multiple nodes simultaneously.
ABOUT PIKTOR
Tumors reroute.PIKTOR seeks to close the exits.
PIKTOR is designed to inhibit PI3K-alpha, mTORC1, and mTORC2. Three nodes. Oral formulation. One therapy.
Single-node inhibitors leave two nodes open. Tumors exploit that gap. By design, PIKTOR engages three nodes simultaneously: PI3K-alpha upstream, mTORC1 and mTORC2 downstream, simultaneously.
OUR SCIENCE
An oral multi-nodePAM Pathway inhibitor.
PIKTOR is designed to deliver multi-node pathway inhibition in an oral formulation.
IV oncology therapies require infusion-center capacity, chair time, and caregiver burden. An oral tablet removes those barriers.
PIPELINE
Three programsBuilt where the science led.
Endometrial Cancer
Phase 2 enrollingBreast Cancer (HR+/HER2-)
Phase 1b enrollingPotential Future Indications
ExploratoryInvestigational drug products. Not approved by the FDA or any other regulatory authority.
OUR MISSION
Weexisttoimprovethelivesofpatientsbydevelopingnoveltherapeuticstotreatsomeofthemostdevastatingtypesofcancer.
OUR TEAM
We refusedthe existing answer.
Faethers name the problem before anyone funds the solution.
Researchers who ran the experiment when the result was uncertain. Clinicians who stayed close to the patient when the data got complicated. Operators who have built before, failed before, and know the difference.
The work is specific. It asks for people who find the constraint interesting, not discouraging. If that sounds like you, we want to meet you.
FAETH